Simponi orchestrates only partial "yes" from Scots despite patient access scheme
This article was originally published in Scrip
The Scottish Medicines Consortium has accepted Merck & Co's anti-TNF-alpha monoclonal antibody Simponi (golimumab) for treating ankylosing spondylitis on the Scottish NHS, but only in doses of 50mg.The consortium has also rejected the use of Bristol-Myers Squibb's Orencia (abatacept) as a second-line treatment rheumatoid arthritis.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.